摘要
目的:探讨脾氨肽降低婴幼儿毛细支气管炎后哮喘发病率的效果。方法:将2010年5月至2012年10月166例毛细支气管住院患儿随机分成干预组与对照组,两组均予常规治疗后痊愈出院。对照组出院后不予药物预防治疗,干预组在出院后口服脾氨肽预防治疗2个月。比较两组患儿1年内支气管哮喘的发病率、临床观察结束(出院1年后)对血清总免疫球蛋白E(IgE)及外周血嗜酸性粒细胞(EOS)计数。结果:干预组87例患儿发生哮喘10例(11.49%),对照组79例患儿发生哮喘27例(34.17%);1年后干预组患儿的IgE与EOS计数比对照组患儿降低更明显,差异均有统计学意义(P<0.05或P<0.01)。结论:脾氨肽在预防婴幼儿毛细支气管炎发展成哮喘方面有肯定的作用,能明显降低哮喘发病率。
OBJECTIVE: To investigate the efficacy of spleen aminopeptidase in reducing the incidence of asthma in infants with bronchiolitis. METHODS: From May 2010 to October 2012, a total of 166 infants with bronchiolitis were randomly assigned to either intervention group or control group. After treatment with routine therapy, all the patients were discharged from hospital. Then only the intervention group was preventively administered with oral spleen aminopeptidase for 2 months. The incidence of bronchial asthma in the two groups within one year were followed, and the total serum immunoglobulin E (IgE) level and peripher- al blood eosinophils (EOS) count were recorded after completion of clinical observation (at 1 year after being discharged from hos- pital). RESULTS: 10 cases in the intervention group (11.49%) versus 87 cases (34.17%) in the control group developed asthma. At 1 year after being discharged from hospital, the reduction in lgE level and peripheral blood eosinophils (EOS) count in the inter- vention group were more significant than in the control group, showing statistically significant differences (P 〈 0.05 or P 〈 0.01 ). CONCLUSIONS: Spleen aminopeptidase has positive preventive efficacy against asthma in the infant for it can significantly reduce the incidence of asthma.
出处
《中国医院用药评价与分析》
2014年第9期786-788,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
脾氨肽
婴幼儿
毛细支气管炎
哮喘
发病率
Spleen aminopeptidase
Infant
Bronchiolitis
Asthma
Incidence